DexCom earnings beat by $0.03, revenue topped estimates
CTT Pharmaceutical (TADAWUL:2070) Holdings NASDAQ:CTTH CEO Ryan Khouri, recently purchased 39,600 shares of company stock. The micro-cap company, currently valued at $1.23 million, has seen its stock decline 71% over the past year, according to InvestingPro data.
The transaction, which occurred on June 26, 2025, involved the purchase of shares at a price of $0.025, for a total value of $990. Following this transaction, Khouri directly owns 6,943,056 shares of CTT Pharmaceutical Holdings. InvestingPro analysis reveals the company’s weak financial health score of 1.29, with the stock trading at historically low Price/Book levels. Get access to 7 more exclusive ProTips and comprehensive insider trading analysis with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.